Business Wire

Helfie AI Bolsters Operational and Strategic Growth With Appointment of Two Influential Industry Leaders to Executive Team

Share

Leadership roles will support continued growth of Helfie AI’s Human Health Network across B2B audiencesKey near-term initiatives will include the official consumer launch of the company’s mobile health checks worldwide

Helfie AI, aglobal mobile health platform, today announced the appointment of two new members of the executive leadership team, Stefan Kulik as Chief Operating Officer and Rania Awad as Chief Strategy Officer.

Helfie AI is building the world’s first human health platform, powered by artificial intelligence, to enable anyone with a smartphone anywhere in the world access to easy, instant and affordable health checks. The additions of Mr. Kulik and Ms. Awad to the leadership team strengthens Helfie AI’s capacity to deliver an AI solution to healthcare that emphasizes data ownership, universal access and freedom of choice, enabling early disease detection and prevention on a global scale.

Helfie AI co-founder and CEO George Tomeski said: “The expansion of our leadership team to include Stefan and Rania is a pivotal moment in Helfie’s growth. As we reach across communities worldwide and deliver on our vision of providing an accurate and cost-effective way for patients to obtain health checks, we will rely on their expertise to realize this mission. I look forward to working with them as we continue to develop our Human Health Network platform to bring it to all 8 billion humans worldwide.”

Kulik has over 15 years of experience serving in executive roles at recognizable companies such as PepsiCo, Johnson & Johnson, and Royal Mail. In each of these leadership roles he developed deep expertise in operational excellence and business development. Kulik also has significant experience in private equity and venture capital environments, with specialized knowledge in predictive analytics and artificial intelligence applications. His unique combination of corporate leadership experience and insights gained from working with elite athletes in performance optimization and behavioural change positions him well to drive Helfie AI's continued growth and strategic objectives.

Awad is an accomplished digital strategist and innovator with extensive experience as a licensed pharmacist and business leader. She brings a proven track record of scaling organizations, spearheading digital transformation initiatives, and developing comprehensive product and go-to-market strategies. Her cross-industry expertise spans healthcare, asset management, retail and information technology sectors, with demonstrated success across the Asia-Pacific region, including Australia, New Zealand, and China. Awad's unique combination of pharmaceutical expertise and strategic business acumen positions her to drive Helfie's strategic vision and market expansion objectives.

​“Helfie AI is revolutionising the healthcare field by providing consumers with a cost-effective and accurate AI-powered platform, so I look forward to applying my organisational expertise to help achieve this vision on a global scale,” said Kulik. “As we expand Helfie AI’s global growth strategy within the UK, broader international markets, and the US, I will work with my colleagues to bring this critical technology to those who need it most.”

“Helfie AI’s technology aims to bring equitable health access globally to bypass complicated healthcare systems and put AI-powered mobile health checks into individual hands,” said Awad. "In the near-term, I will use my expertise in strategic marketing to help Helfie AI achieve its next stage of growth, which includes a consumer launch and expanded partnerships with organizations and governments worldwide. I’m confident that the expanded leadership team will deliver on Helfie AI’s mission to become the most trusted AI health company in the market.”

Helfie AI's advanced AI technologies analyse pictures, videos, sound recordings or face scans to check for indications of potential health conditions. Helfie AI generates instant results and offers the user information and options on what to do next. Importantly, the user owns and controls all of the data provided as part of the checks.

About Helfie AI
Helfie AI was founded in Melbourne, Australia in 2021 and has expanded operations to Europe, North America, Africa and Asia with multiple active B2B partnerships with top tier companies already in place.

Helfie AI tackles two of healthcare’s most fundamental challenges: the lack of participation in preventative healthcare and the under-utilisation of health data. Every facet of healthcare, starting with the quality and longevity of human life, can be dramatically improved if everyone actively participates in preventative health and if health data is actively utilized throughout the healthcare system.

The accessibility made possible by Helfie AI can significantly reduce the $7 trillion spent annually on treating preventable conditions.

Helfie AI provides users with clear next steps, connects them to medical care if/as required, allows interaction around numerous health conditions, from cardiovascular to skin health, and enables sharing AI findings with their own carers and doctors.

More details on the checks Helfie can make are available at www.helfie.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731802386/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

San’an and Inari to Acquire 100% of Lumileds Holding B.V.’s Shares1.8.2025 11:05:00 CEST | Press release

San’an Optoelectronics and Inari Amertron Berhad today announced they have entered into a definitive agreement to acquire Lumileds Holding B.V. and its European and Asian subsidiaries (“Lumileds International”). “This transaction is the next step of our ongoing transformation. As the LED industry evolves and continues to mature, I am confident that Lumileds International will continue to be successful and accelerate its growth under the new ownership,” said Steve Barlow, CEO of Lumileds International. The transaction is expected to close by the first quarter of 2026, subject to customary closing conditions. About Lumileds International Lumileds International is a global leader in LED technology, innovation, and solutions for the automotive, display, illumination, mobile, and other markets where light sources are essential. Our approximately 3,300 employees operate in over 15 countries to partner with our customers to deliver solutions for lighting, safety, and well-being. About San’an

Rimini Street Announces Fiscal Second Quarter 2025 Financial and Operating Results31.7.2025 22:01:00 CEST | Press release

Second Quarter Financial Highlights Include: Gross margin of 60.4% compared to 59.1% in the prior year Adjusted Calculated Billings of $107.9 million compared to $103.8 million in the prior year Adjusted EBITDA of $13.0 million compared to $8.8 million in the prior year Revenue Retention Rate of 90% compared to 88% in the prior year Rimini Street, Inc., (the “Company”) (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731791846/en/ Rimini Street Announces Fiscal Second Quarter 2025 Financial and Operating Results Select Second Quarter 2025 Financial Results Revenue was $104.1 million for the 2025 second quarter, an increase of 1.0% compared to $103.1 million for the same

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development31.7.2025 20:56:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. This partnership combines Altasciences’ comprehensive early-phase drug development capabilities with VoxCell’s cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell’s high-resolution 3D bioprinted tissue platforms into Altasciences’ discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies. “We’re proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “This collaboration aligns with

GEA Raises Forecast for Fiscal Year 2025 and Provides Positive Outlook31.7.2025 19:40:00 CEST | Press release

Due to a very positive operating performance in the first 6 months and expectations for the remainder of the financial year 2025, GEA Group Aktiengesellschaft is raising all guidance parameters based on preliminary figures as follows: Organic sales growth 2 to 4 percent (previously 1 to 4 percent), EBITDA-margin before restructuring expenses 16.2 to 16.4 percent (previously 15.6 to 16.0 percent) and ROCE 34 to 38 percent (previously 30 to 35 percent). The company will publish its complete statement for the 2nd quarter (half-year financial report) on August 7, 2025. “Our positive development continues. The additional improvements are broad-based, supported by a favorable order situation as well as margin improvements and efficiency gains across the Group. Once again, we are thus demonstrating our strength in executing on our plans,” said GEA CEO Stefan Klebert. Alongside improving the profitability indicators EBITDA margin before restructuring expenses and ROCE, GEA also increased order

Global Technology Leaders Adopt Access Advance's Video Distribution Patent Pool31.7.2025 18:58:00 CEST | Press release

A diverse group of global companies across the video ecosystem has joined Access Advance's Video Distribution Patent ("VDP") Pool and is now sharing why they selected this pool. Positioned as a balanced, transparent, and comprehensive video codec licensing solution for the video streaming industry, the pool brings together major patent holders, video platform operators, and stakeholders in the consumer device market in an effort to help the industry navigate the complex licensing challenges in the rapidly evolving video distribution markets. The VDP Pool has attracted an unprecedented list of industry leaders as both licensors and licensees, including ByteDance, Dolby, JVC Kenwood, Kuaishou, HFI (an affiliate of MediaTek), Mitsubishi, OPPO, Philips, Tencent, and other major technology companies. This broad participation spans the entire video ecosystem, from content platforms serving billions of users to semiconductor companies powering video devices worldwide. Collaborative Framework

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye